Loading...
XETR
GME
Market cap20mUSD
Apr 11, Last price  
3.35EUR
1D
2.76%
1Q
-8.97%
Jan 2017
-71.51%
Name

Geratherm Medical AG

Chart & Performance

D1W1MN
P/E
16.32
P/S
0.81
EPS
0.21
Div Yield, %
2.99%
Shrs. gr., 5y
1.80%
Rev. gr., 5y
0.71%
Revenues
22m
-13.73%
7,735,1288,459,6728,589,6138,802,00310,734,56414,914,43617,783,09718,981,11116,280,27617,029,04018,714,64121,588,89522,062,98421,030,77921,521,92019,851,17627,466,23024,638,67325,850,61922,300,873
Net income
1m
+8.57%
1,332,7051,426,91900-2,920,6172,678,5452,542,2901,095,1151,194,1901,333,7811,682,3592,701,2652,236,805679,7871,153,595289,8572,045,328332,6471,023,4461,111,156
CFO
1m
-45.09%
871,000860,000240,9201,038,620473,0002,710,000427,0001,063,0001,605,0002,438,000952,0003,774,000792,0002,466,0001,347,0001,540,0003,915,000917,0002,606,0001,431,000
Dividend
Aug 19, 20240.1 EUR/sh

Profile

Geratherm Medical AG operates as a medical technology company in Germany. It operates through Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems segments. The Healthcare Diagnostic segment provides clinical thermometers; blood pressure monitors; and self-test diagnostic products for women, including pregnancy tests, chlamydia tests, urinary tract infections, diverse ovulation test solutions, and pH tests. The Respiratory segment develops and manufactures products primarily for pulmonary and cardiopulmonary function diagnostics. The Medical Warming Systems segment offers MRI-compatible incubators for premature and newborn infants under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation. The company markets its products through pharmacies, hospitals, and clinics. It exports its products to approximately 60 countries. The company was founded in 1990 and is headquartered in Geschwenda, Germany.
URL
https://www.geratherm.de
IPO date
Jul 03, 2000
Employees
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
22,301
-13.73%
25,851
4.92%
Cost of revenue
19,943
25,717
Unusual Expense (Income)
NOPBT
2,357
134
NOPBT Margin
10.57%
0.52%
Operating Taxes
645
631
Tax Rate
27.38%
471.77%
NOPAT
1,712
(497)
Net income
1,111
8.57%
1,023
207.67%
Dividends
(813)
(653)
Dividend yield
Proceeds from repurchase of equity
(233)
4,207
BB yield
Debt
Debt current
3,237
3,474
Long-term debt
7,231
9,295
Deferred revenue
1,429
1,515
Other long-term liabilities
2,880
252
Net debt
2,097
1,021
Cash flow
Cash from operating activities
1,431
2,606
CAPEX
(758)
(2,739)
Cash from investing activities
(2,307)
(985)
Cash from financing activities
(2,835)
4,749
FCF
4,563
(5,681)
Balance
Cash
7,745
10,886
Long term investments
626
862
Excess cash
7,256
10,455
Stockholders' equity
5,852
4,604
Invested Capital
25,895
32,799
ROIC
5.83%
ROCE
7.40%
0.36%
EV
Common stock shares outstanding
5,412
5,445
Price
Market cap
EV
EBITDA
2,359
1,610
EV/EBITDA
Interest
153
179
Interest/NOPBT
6.49%
134.16%